Janus Henderson Group PLC Raises Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

Janus Henderson Group PLC boosted its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 17.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 80,069 shares of the company's stock after buying an additional 11,800 shares during the quarter. Janus Henderson Group PLC's holdings in Hims & Hers Health were worth $1,936,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the business. Jasper Ridge Partners L.P. raised its position in Hims & Hers Health by 3.6% during the 4th quarter. Jasper Ridge Partners L.P. now owns 110,825 shares of the company's stock worth $2,680,000 after buying an additional 3,812 shares during the last quarter. Jefferies Financial Group Inc. acquired a new position in Hims & Hers Health during the fourth quarter valued at $4,900,000. Gotham Asset Management LLC acquired a new position in Hims & Hers Health during the fourth quarter valued at $440,000. Farallon Capital Management LLC lifted its position in Hims & Hers Health by 64,338.5% during the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock valued at $202,556,000 after purchasing an additional 8,364,000 shares during the period. Finally, FORA Capital LLC lifted its position in Hims & Hers Health by 81.7% during the fourth quarter. FORA Capital LLC now owns 139,139 shares of the company's stock valued at $3,364,000 after purchasing an additional 62,553 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Performance

Shares of NYSE:HIMS traded up $1.37 during midday trading on Friday, reaching $54.89. 23,551,640 shares of the company's stock traded hands, compared to its average volume of 19,610,998. Hims & Hers Health, Inc. has a 1 year low of $13.47 and a 1 year high of $72.98. The company has a market cap of $12.29 billion, a P/E ratio of 124.75 and a beta of 1.84. The company has a fifty day simple moving average of $37.95 and a two-hundred day simple moving average of $35.16.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.12 by $0.08. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $586.01 million for the quarter, compared to analyst estimates of $535.21 million. During the same quarter last year, the firm posted $0.05 EPS. The business's revenue was up 110.7% on a year-over-year basis. As a group, research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analysts Set New Price Targets

HIMS has been the subject of a number of research reports. TD Cowen downgraded shares of Hims & Hers Health from a "buy" rating to a "hold" rating and decreased their target price for the company from $44.00 to $30.00 in a research report on Tuesday, April 29th. Citigroup restated a "sell" rating and issued a $30.00 target price (up previously from $25.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Needham & Company LLC restated a "buy" rating and issued a $61.00 target price on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Piper Sandler reaffirmed a "neutral" rating and set a $39.00 price objective (up previously from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Finally, Bank of America raised their price objective on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a research note on Tuesday, April 29th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, Hims & Hers Health currently has an average rating of "Hold" and a consensus price target of $37.67.

Insider Transactions at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 11,581 shares of the stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $60.22, for a total value of $697,407.82. Following the completion of the transaction, the chief financial officer now directly owns 113,816 shares of the company's stock, valued at approximately $6,853,999.52. This represents a 9.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Andrew Dudum sold 47,534 shares of the stock in a transaction on Friday, May 16th. The shares were sold at an average price of $58.25, for a total value of $2,768,855.50. Following the completion of the transaction, the chief executive officer now directly owns 285,194 shares of the company's stock, valued at approximately $16,612,550.50. This represents a 14.29% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 618,936 shares of company stock valued at $25,182,692 over the last 90 days. Corporate insiders own 13.71% of the company's stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.